Utilization of intravenous thrombolysis is increasing in the United States

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Evaluating recombinant tissue plasminogen activator utilization rates is important, as many studies have demonstrated that administration of recombinant tissue plasminogen activator to qualified patients significantly improves prognosis. Aims: We investigated recent trends in the utilization and outcomes of administration of intravenous recombinant tissue plasminogen activator in the United States using the National Inpatient Sample between 2001 and 2008. Methods: We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage. Information on demographics, hospital characteristics, and comorbidities was collected. A multivariate logistic regression analysis was performed to determine independent predictors of morbidity, mortality, and intracranial hemorrhage. Results: Intravenous recombinant tissue plasminogen activator utilization increased from 1·3% in 2001 to 3·5% in 2008. On multivariate analysis, variables associated with increased morbidity after intravenous recombinant tissue plasminogen activator administration included advanced age (P<0·001), female gender (P<0·001), and comorbidities of atrial fibrillation (P<0·001) and hypertension (P<0·001). Increased mortality was associated with increased age (P<0·001) and comorbidities of atrial fibrillation, congestive heart failure, coronary artery disease, and diabetes (P<0·001 for all comorbidities). Conclusions: Intravenous recombinant tissue plasminogen activator utilization rates increased between 2001 and 2008. Advanced age and atrial fibrillation were significantly associated with increased morbidity and mortality among patients treated with intravenous recombinant tissue plasminogen activator.

Original languageEnglish (US)
Pages (from-to)681-688
Number of pages8
JournalInternational Journal of Stroke
Volume8
Issue number8
DOIs
StatePublished - Nov 27 2013

Fingerprint

Tissue Plasminogen Activator
Comorbidity
Atrial Fibrillation
Morbidity
Intracranial Hemorrhages
Mortality
Hospital Mortality
Intravenous Administration
Inpatients
Coronary Artery Disease
Multivariate Analysis
Heart Failure
Logistic Models
Stroke
Regression Analysis
Demography
Hypertension

Keywords

  • Acute stroke therapy
  • Epidemiology
  • Ischemic stroke
  • Neurology
  • rtPA
  • Socioeconomic factors

ASJC Scopus subject areas

  • Neurology

Cite this

Utilization of intravenous thrombolysis is increasing in the United States. / Nasr, Deena; Brinjikji, Waleed; Cloft, Harry J.; Rabinstein, Alejandro.

In: International Journal of Stroke, Vol. 8, No. 8, 27.11.2013, p. 681-688.

Research output: Contribution to journalArticle

@article{b1313e8a6f624a42839a57fb7361dffc,
title = "Utilization of intravenous thrombolysis is increasing in the United States",
abstract = "Background: Evaluating recombinant tissue plasminogen activator utilization rates is important, as many studies have demonstrated that administration of recombinant tissue plasminogen activator to qualified patients significantly improves prognosis. Aims: We investigated recent trends in the utilization and outcomes of administration of intravenous recombinant tissue plasminogen activator in the United States using the National Inpatient Sample between 2001 and 2008. Methods: We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage. Information on demographics, hospital characteristics, and comorbidities was collected. A multivariate logistic regression analysis was performed to determine independent predictors of morbidity, mortality, and intracranial hemorrhage. Results: Intravenous recombinant tissue plasminogen activator utilization increased from 1·3{\%} in 2001 to 3·5{\%} in 2008. On multivariate analysis, variables associated with increased morbidity after intravenous recombinant tissue plasminogen activator administration included advanced age (P<0·001), female gender (P<0·001), and comorbidities of atrial fibrillation (P<0·001) and hypertension (P<0·001). Increased mortality was associated with increased age (P<0·001) and comorbidities of atrial fibrillation, congestive heart failure, coronary artery disease, and diabetes (P<0·001 for all comorbidities). Conclusions: Intravenous recombinant tissue plasminogen activator utilization rates increased between 2001 and 2008. Advanced age and atrial fibrillation were significantly associated with increased morbidity and mortality among patients treated with intravenous recombinant tissue plasminogen activator.",
keywords = "Acute stroke therapy, Epidemiology, Ischemic stroke, Neurology, rtPA, Socioeconomic factors",
author = "Deena Nasr and Waleed Brinjikji and Cloft, {Harry J.} and Alejandro Rabinstein",
year = "2013",
month = "11",
day = "27",
doi = "10.1111/j.1747-4949.2012.00844.x",
language = "English (US)",
volume = "8",
pages = "681--688",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Utilization of intravenous thrombolysis is increasing in the United States

AU - Nasr, Deena

AU - Brinjikji, Waleed

AU - Cloft, Harry J.

AU - Rabinstein, Alejandro

PY - 2013/11/27

Y1 - 2013/11/27

N2 - Background: Evaluating recombinant tissue plasminogen activator utilization rates is important, as many studies have demonstrated that administration of recombinant tissue plasminogen activator to qualified patients significantly improves prognosis. Aims: We investigated recent trends in the utilization and outcomes of administration of intravenous recombinant tissue plasminogen activator in the United States using the National Inpatient Sample between 2001 and 2008. Methods: We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage. Information on demographics, hospital characteristics, and comorbidities was collected. A multivariate logistic regression analysis was performed to determine independent predictors of morbidity, mortality, and intracranial hemorrhage. Results: Intravenous recombinant tissue plasminogen activator utilization increased from 1·3% in 2001 to 3·5% in 2008. On multivariate analysis, variables associated with increased morbidity after intravenous recombinant tissue plasminogen activator administration included advanced age (P<0·001), female gender (P<0·001), and comorbidities of atrial fibrillation (P<0·001) and hypertension (P<0·001). Increased mortality was associated with increased age (P<0·001) and comorbidities of atrial fibrillation, congestive heart failure, coronary artery disease, and diabetes (P<0·001 for all comorbidities). Conclusions: Intravenous recombinant tissue plasminogen activator utilization rates increased between 2001 and 2008. Advanced age and atrial fibrillation were significantly associated with increased morbidity and mortality among patients treated with intravenous recombinant tissue plasminogen activator.

AB - Background: Evaluating recombinant tissue plasminogen activator utilization rates is important, as many studies have demonstrated that administration of recombinant tissue plasminogen activator to qualified patients significantly improves prognosis. Aims: We investigated recent trends in the utilization and outcomes of administration of intravenous recombinant tissue plasminogen activator in the United States using the National Inpatient Sample between 2001 and 2008. Methods: We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage. Information on demographics, hospital characteristics, and comorbidities was collected. A multivariate logistic regression analysis was performed to determine independent predictors of morbidity, mortality, and intracranial hemorrhage. Results: Intravenous recombinant tissue plasminogen activator utilization increased from 1·3% in 2001 to 3·5% in 2008. On multivariate analysis, variables associated with increased morbidity after intravenous recombinant tissue plasminogen activator administration included advanced age (P<0·001), female gender (P<0·001), and comorbidities of atrial fibrillation (P<0·001) and hypertension (P<0·001). Increased mortality was associated with increased age (P<0·001) and comorbidities of atrial fibrillation, congestive heart failure, coronary artery disease, and diabetes (P<0·001 for all comorbidities). Conclusions: Intravenous recombinant tissue plasminogen activator utilization rates increased between 2001 and 2008. Advanced age and atrial fibrillation were significantly associated with increased morbidity and mortality among patients treated with intravenous recombinant tissue plasminogen activator.

KW - Acute stroke therapy

KW - Epidemiology

KW - Ischemic stroke

KW - Neurology

KW - rtPA

KW - Socioeconomic factors

UR - http://www.scopus.com/inward/record.url?scp=84888094762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888094762&partnerID=8YFLogxK

U2 - 10.1111/j.1747-4949.2012.00844.x

DO - 10.1111/j.1747-4949.2012.00844.x

M3 - Article

VL - 8

SP - 681

EP - 688

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 8

ER -